# Life Sciences Fund Amsterdam

Life Sciences Fund Amsterdam is a Private Equity based in Amsterdam, Netherlands.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Amsterdam, Netherlands
- **Region:** Europe
- **Address:** Amsterdam, Netherlands
- **Founded:** 2009
- **Assets under management:** Undisclosed
- **Website:** lsfamsterdam.nl
- **LinkedIn:** https://www.linkedin.com/company/life-sciences-fund-amsterdam

## Regulatory record

- **Reports private funds:** No

## About

Life Sciences Fund Amsterdam is a private equity firm based in Amsterdam, Netherlands. It focuses on a Venture Capital strategy.

## Sectors

- Life Sciences
- Digital Health
- Healthcare Services

## People

- Paul Kloppenborg — Investment Manager

## Questions

### How does Life Sciences Fund Amsterdam source its deal flow?

The firm sources primarily through technology transfer offices at Dutch research universities and academic medical centers, notably those in the Amsterdam-Leiden-Utrecht triangle. It also reviews corporate divestiture opportunities from the Netherlands' multinational pharmaceutical and medtech base. This proximity-driven model gives it early access to spin-outs before they reach pan-European venture syndicates.

### Does the firm invest outside the Netherlands?

The primary focus is the Amsterdam-Leiden-Utrecht corridor, which hosts the highest concentration of life science spin-out activity in the country. The firm has selectively placed capital in Flanders and the Nordic region, though no dedicated satellite offices exist outside Amsterdam.

### Who manages investment decisions?

Paul Kloppenborg serves as Investment Manager and is the named principal associated with the firm's deal execution. The broader team is compact, operating from a single Amsterdam office without a publicly disclosed investment committee structure.

### Is Life Sciences Fund Amsterdam structured as a fund-of-funds or does it invest directly?

The firm invests directly into companies, not through fund-of-funds allocations. It leads or co-leads seed rounds and participates in syndicated venture rounds alongside regional development agencies and specialist health-tech investors.

### What types of life science companies does the firm avoid?

No explicit exclusion list has been published. Given the firm's size, geography, and academic sourcing model, large-late-stage therapeutics companies requiring hundred-million-euro clinical trials or pure service businesses without proprietary technology are inconsistent with the observed mandate.

## Related profiles

- [Life Science Innovations](https://altss.com/profile/life-sci-ence-inno-va-tions)
- [LifeSci Partners](https://altss.com/profile/lifesci-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/life-sciences-fund-amsterdam

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology